Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open-Label, Dose-Escalation and Clinical Response Study of Quaratusugene Ozeplasmid in Combination With Osimertinib in Patients With Advanced, Metastatic EGFR-Mutant, Metastatic Non-Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 22 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Osimertinib (Primary) ; Quaratusugene ozeplasmid (Primary) ; Carboplatin; Cisplatin; Dexamethasone; Diphenhydramine; Paracetamol; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms Acclaim-1
  • Sponsors Genprex

    • Most Recent Events

    • 15 Aug 2024 Results published in the Genprex Media Release
    • 14 Aug 2024 According to a Genprex media release, company will conduct an interim analysis following the treatment of 19 patients in the Phase 2a expansion portion.
    • 14 Aug 2024 According to a Genprex media release,based on resource prioritization and to focus on the patients for whom REQORSA is most likely to show a benefit,Company has decided to limit its enrollment efforts to patients who received only prior Tagrisso treatment and to cease enrollment of the 2nd cohort (patients who received prior Tagrisso treatment and chemotherapy).The Phase 2a expansion portion with one cohort is now expected to enroll approx 33 patients and phase 2b remains unchanged.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top